Nov. 11, 1998: Patients with open-angle glaucoma switched to Xalatan (latanoprost ophthalmic solution) monotherapy experienced the same reduction in intraocular pressure (IOP) as do patients taking a combination of timolol (a commonly used beta blocker) and dorzolamide (a carbonic anhydrase inhibitor), according to German researchers. Open-angle glaucoma is a leading cause of blindness.

Discussion group for Xalatan and latanoprost patients.

March 15, 1999: Xalatan has been approved in more than 57 countries and is the leading prescribed glaucoma medication in severalm markets, including the United States.